Andrew Srisuwananukorn, MD, on Myelofibrosis vs Essential Thrombocythemia: A Potential New Clinical Decision Tool 
    		2023 ASH
    	
    	
    	
    
        Andrew Srisuwananukorn, MD, of The Ohio State University Comprehensive Cancer Center, discusses a novel artificial intelligence model that can distinguish between prefibrotic primary myelofibrosis and essential thrombocythemia. This proposed model may assist clinicians in identifying patients who may benefit from disease-specific therapies or enrollment in clinical trials (Abstract 901).
    
    
    
    
       
       
    		The ASCO Post Staff
		
		
        
		
		
		
		Mikkael A. Sekeres, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, reviews key abstracts from ASH 2023 on treatment of myelofibrosis, chronic lymphocytic leukemia, large B-cell lymphoma, and acute myeloid leukemia (Abstracts 620, 631, 781, 425).
			
			
     	
    
       
       
    		The ASCO Post Staff
		
		
        
		
		
		
		Bijal D. Shah, MD, of Moffitt Cancer Center and Research Institute, discusses a matching-adjusted indirect comparison of brexucabtagene autoleucel and pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma who have been previously treated with a BTK inhibitor (Abstract 5136).
			
			
     	
    
       
       
    		The ASCO Post Staff
		
		
        
		
		
		
		Sanjal H. Desai, MBBS, of the University of Minnesota, discusses results from a multicenter cohort, which shows that, for transplant-eligible patients with relapsed or refractory classical Hodgkin lymphoma, PD-1–based salvage therapy at any point before transplantation is associated with improved progression-free survival, compared with brentuximab vedotin or chemotherapy-based salvage regimens (Abstract 182).
			
			
     	
    
       
       
    		The ASCO Post Staff
		
		
        
		
		
		
		Jonathon B. Cohen, MD, of Winship Cancer Institute, Emory University, discusses safety and efficacy findings from the phase I/II BRUIN study. The trial found that pirtobrutinib continues to demonstrate durable efficacy and a favorable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma (Abstract 981).
			
			
     	
    
       
       
    		The ASCO Post Staff
		
		
        
		
		
		
		Jeffrey E. Rubnitz, MD, PhD, of St. Jude Children’s Research Hospital, discusses study findings suggesting that pharmacogenomic differences between Black and White patients should be considered when tailoring induction regimens to improve outcomes of all patients and bridge the racial disparity gap in acute myeloid leukemia treatment (Abstract 386).